For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs ...

In honor of American Heart Month, Healio Dermatology interviewed experts and explored the connection between skin disease and heart health.The discovery of this relationship can be traced back to ...

Many patients with overweight or obesity discontinue glucagon-like peptide-1 receptor agonist therapy within one year.

The Hong Kong company saw a reduction in body weight across both cohorts with no serious adverse events reported.

Insulin resistance precedes and predicts the onset of type 2 diabetes mellitus (DM2), a chronic disease that causes high morbidity and mortality worldwide. In affected people, insulin is unable to ...

Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...

Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...

The new weight loss drug offers promising results for those who are overweight or obese. Learn about how Zepbound works, its ...

UK: A recent consensus statement from leading UK medical organizations—including the Association of Anaesthetists, the ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...